{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:21:52Z","timestamp":1715962912527},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"S9","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A key challenge in pharmacogenomics is the identification of genes whose variants contribute to drug response phenotypes, which can include severe adverse effects. Pharmacogenomics GWAS attempt to elucidate genotypes predictive of drug response. However, the size of these studies has severely limited their power and potential application. We propose a novel knowledge integration and SNP aggregation approach for identifying genes impacting drug response. Our SNP aggregation method characterizes the degree to which uncommon alleles of a gene are associated with drug response. We first use pre-existing knowledge sources to rank pharmacogenes by their likelihood to affect drug response. We then define a summary score for each gene based on allele frequencies and train linear and logistic regression classifiers to predict drug response phenotypes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We applied our method to a published warfarin GWAS data set comprising 181 individuals. We find that our method can increase the power of the GWAS to identify both VKORC1 and CYP2C9 as warfarin pharmacogenes, where the original analysis had only identified VKORC1. Additionally, we find that our method can be used to discriminate between low-dose (AUROC=0.886) and high-dose (AUROC=0.764) responders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our method offers a new route for candidate pharmacogene discovery from pharmacogenomics GWAS, and serves as a foundation for future work in methods for predictive pharmacogenomics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2105-11-s9-s9","type":"journal-article","created":{"date-parts":[[2010,10,28]],"date-time":"2010-10-28T18:15:23Z","timestamp":1288289723000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["An integrative method for scoring candidate genes from association studies: application to warfarin dosing"],"prefix":"10.1186","volume":"11","author":[{"given":"Nicholas P","family":"Tatonetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel T","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hersh","family":"Sagreiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul J","family":"Butte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ B","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,28]]},"reference":[{"issue":"4","key":"4271_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/gm46","volume":"1","author":"I Guessous","year":"2009","unstructured":"Guessous I, Gwinn M, Khoury MJ: Genome-wide association studies in pharmacogenomics: untapped potential for translation. Genome Med 2009, 1(4):46. 10.1186\/gm46","journal-title":"Genome Med"},{"issue":"2","key":"4271_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/14622416.10.2.157","volume":"10","author":"D Gurwitz","year":"2009","unstructured":"Gurwitz D, Mcleod HL: Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics 2009, 10(2):157\u2013159. 10.2217\/14622416.10.2.157","journal-title":"Pharmacogenomics"},{"issue":"8","key":"4271_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SC Group","year":"2008","unstructured":"Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R: SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008, 359(8):789\u2013799. 10.1056\/NEJMoa0801936","journal-title":"N Engl J Med"},{"issue":"2","key":"4271_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/tpj.2008.17","volume":"9","author":"Y Sato","year":"2009","unstructured":"Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R, et al.: A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. The Pharmacogenomics Journal 2009, 9(2):137\u2013146. 10.1038\/tpj.2008.17","journal-title":"The Pharmacogenomics Journal"},{"issue":"4","key":"4271_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FPC.0b013e3282f70492","volume":"18","author":"T Inada","year":"2008","unstructured":"Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T: Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008, 18(4):317\u2013323. 10.1097\/FPC.0b013e3282f70492","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"4271_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00439-008-0600-y","volume":"125","author":"K Askland","year":"2009","unstructured":"Askland K, Read C, Moore J: Pathways-based analyses of whole-genome association study data in bipolar disorder reveal genes mediating ion channel activity and synaptic neurotransmission. Hum Genet 2009, 125(1):63\u201379. 10.1007\/s00439-008-0600-y","journal-title":"Hum Genet"},{"key":"4271_CR7","volume-title":"Pharmacogenomics","author":"J Crowley","year":"2009","unstructured":"Crowley J, Sullivan P, McLeod H: Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009."},{"issue":"10","key":"4271_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","volume":"165","author":"AM Holbrook","year":"2005","unstructured":"Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Archives of Internal Medicine 2005, 165(10):1095\u20131106. 10.1001\/archinte.165.10.1095","journal-title":"Archives of Internal Medicine"},{"issue":"21","key":"4271_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352(21):2211\u20132221. 10.1056\/NEJMra032424","journal-title":"N Engl J Med"},{"issue":"3","key":"4271_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","volume":"12","author":"CR Lee","year":"2002","unstructured":"Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12(3):251\u2013263. 10.1097\/00008571-200204000-00010","journal-title":"Pharmacogenetics"},{"issue":"2","key":"4271_CR11","doi-asserted-by":"publisher","first-page":"645-","DOI":"10.1182\/blood-2004-06-2111","volume":"105","author":"G D'Andrea","year":"2005","unstructured":"D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105(2):645--649. 10.1182\/blood-2004-06-2111","journal-title":"Blood"},{"issue":"8","key":"4271_CR12","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1182\/blood-2007-11-122010","volume":"111","author":"MD Caldwell","year":"2008","unstructured":"Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111(8):4106\u20134112. 10.1182\/blood-2007-11-122010","journal-title":"Blood"},{"issue":"4","key":"4271_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.tpj.6500313","volume":"5","author":"M Wadelius","year":"2005","unstructured":"Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The Pharmacogenomics Journal 2005, 5(4):262\u2013270. 10.1038\/sj.tpj.6500313","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"4271_CR14","doi-asserted-by":"publisher","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","volume":"5","author":"F Takeuchi","year":"2009","unstructured":"Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al.: A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5(3):e1000433. 10.1371\/journal.pgen.1000433","journal-title":"PLoS Genet"},{"issue":"4","key":"4271_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","volume":"112","author":"GM Cooper","year":"2008","unstructured":"Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, et al.: A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112(4):1022\u20131027. 10.1182\/blood-2008-01-134247","journal-title":"Blood"},{"issue":"8","key":"4271_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"IWP Consortium","year":"2009","unstructured":"Consortium IWP, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee M-TM, Limdi NA, Page D, Roden DM, et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360(8):753\u2013764. 10.1056\/NEJMoa0809329","journal-title":"N Engl J Med"},{"issue":"2","key":"4271_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/clpt.2009.42","volume":"86","author":"NT Hansen","year":"2009","unstructured":"Hansen NT, Brunak S, Altman RB: Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009, 86(2):183\u2013189. 10.1038\/clpt.2009.42","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4271_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/75360","volume":"18","author":"JJ McCarthy","year":"2000","unstructured":"McCarthy JJ, Hilfiker R: The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000, 18(5):505\u2013508. 10.1038\/75360","journal-title":"Nat Biotechnol"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2105-11-S9-S9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:47:04Z","timestamp":1630496824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/1471-2105-11-S9-S9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":18,"journal-issue":{"issue":"S9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1186\/1471-2105-11-s9-s9","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"28 October 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S9"}}